Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells

Cytometry Part A

Volumn 71, Issue 11, 2007, Pages 945-950

  Forster, Martin D ^a   Ormerod, Michael G ^a   Agarwal, Roshan ^a   Kaye, Stanley B ^a   Jackman, Ann L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Flow cytometry; Folate receptor; Ovarian carcinoma

Indexed keywords

CD45 ANTIGEN; CELL MARKER; FLUORESCEIN; FOLATE RECEPTOR; FOLATE RECEPTOR ANTIBODY; PHYCOERYTHRIN; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER SCREENING; CELL POPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY;

ASCITIC FLUID; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 35948960350     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20456     Document Type: Article

References (12)

1. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-293.
2. Veggian R, Fasolato S, Menard S, Minucci D, Pizzetti P, Regazzoni M, Tagliabue E, Colnaghi MI. Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori 1989;75:510-513.
3. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142:557-567.
4. Mantovani LT, Miotti S, Menard S, Canevari S, Raspagliesi F, Bottini C, Bottero F, Colnaghi MI. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 1994;30A:363-369.
5. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1994;74:193-198.
6. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999;8:775-782.
7. Toffoli G, Russo A, Gallo A, Cernigoi C, Miottt S, Sorto R, Tumolo S, Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998;79:121-126.
8. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005;65:11721-11728.
9. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 2004;73:2432-2443.
10. Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjamer A, Berner A. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999;435:43-49.
11. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: Stepwise logistic regression analysis. Cytopathology 2000;11:8-17.
12. Fetsch PA, Simsir A, Brosky K, Absti A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2001;26:61-66.